Clinical trials: Prostatic Disease
Prostate Cancer
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve.
- Trial name
- NCT00654186
- Testing
- Revlimid
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Oncology Specialists, S.C.
Prostate Cancer, Prostatic Cancer
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer.
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostate Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00643994
- Testing
- CyberKnife Stereotactic Radiosurgery
- Where
- 23 sites in United States
- Volunteers
- 379 people
- Sponsor
- Accuray Incorporated
Ovarian Cancer, Breast Cancer
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Background: All cells go through cycles which allow them to divide. In normal cells, checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) (CHEK 2 (Chk1/2) stop cell division at various points to allow any damage to…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02203513
- Testing
- LY2606368
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
- Trial name
- NCT00901342
- Testing
- sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 104 people
- Sponsor
- Dendreon
Prostate Cancer
Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI
There is great need for improved preoperative imaging in men with high-risk prostate cancer. Investigators propose to develop and validate an optimized simultaneous PET/MRI protocol for local, regional and whole body preoperative…
- Trial name
- NCT03264456
- Testing
- [18F] Fluciclovine PET/MRI, [18F] fluciclovine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Alabama at Birmingham
Prostate Neoplasms
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
The purpose of this study is to assess the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer (a disease in which cells in the prostate gland [a gland in the male reproductive system…
- Trial name
- NCT00474383
- Testing
- Abiraterone acetate, Glucocorticoid
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 47 people
- Sponsor
- Cougar Biotechnology, Inc.
Prostate Cancer
A Study of Olaparib and Durvalumab in Prostate Cancer
The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.
- Trial name
- NCT03810105
- Testing
- Olaparib, Durvalumab
- Where
- 8 sites in United States
- Volunteers
- 5 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Hyperplasia
Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects
This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.
- Trial name
- NCT00368979
- Testing
- Dutasteride
- Where
- 26 sites in Japan
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors, Solid Tumors
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid-filled soft gelatin capsule (soft…
- Conditions
- Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer
- Trial name
- NCT04672460
- Testing
- TALZENNA capsule, Talazoparib soft gel capsule
- Where
- 31 sites in United States, Australia
- Volunteers
- 73 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Metastatic Prostate Cancer
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
This study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to…
- Trial name
- NCT04262154
- Testing
- Atezolizumab, Abiraterone, Prednisone
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Prostate Cancer Metastatic
MSG Use With 18F-DCFPyL PET/CT Imaging
18F-DCFPyL is an agent that binds to prostate specific membrane antigen (PSMA). Due to high levels of PSMA in prostate cancer, treatments targeting PSMA have been developed to deliver therapy to these specific target cells.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasm
- Trial name
- NCT03693742
- Testing
- 18F-DCFPyL PET/CT scan, MSG drink
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Efavirenz in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate…
- Trial name
- FAVE (NCT00964002)
- Testing
- efavirenz
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Institut Bergonié
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic…
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01270880
- Testing
- Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
This randomized phase II trial studies how well docetaxel works when given with or without ascorbic acid in treating patients with prostate cancer that has spread to other places in the body.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT02516670
- Testing
- Ascorbic Acid, Docetaxel, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate…
- Trial name
- NCT02555397
- Testing
- Ad5-yCD/mutTKSR39rep-hIL12
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Prostate Cancer
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
This research study is being done to measure the clinical benefit of TRC105 in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or…
- Trial name
- NCT03418324
- Testing
- TRC105, Abiraterone, Enzalutamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Prostatic Neoplasms, Prostate Cancer
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
Background: Men who continue to have an elevated or rising prostate specific antigen (PSA) level after their primary prostate cancer treatment are at increased risk for their cancer to progress.
- Trial name
- NCT02362451
- Testing
- Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
This was an open-label, multi-centre, uncontrolled, exploratory trial with a duration of 12 months in two cohorts. The trial aimed to investigate Degarelix as a second-line hormonal treatment in Prostate Cancer patients who…
- Trial name
- NCT00738673
- Testing
- degarelix
- Where
- 15 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Ferring Pharmaceuticals
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
This randomized phase III trial is studying docetaxel, prednisone, and bevacizumab to see how well they work compared to docetaxel and prednisone in treating patients with prostate cancer that did not respond to hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00110214
- Testing
- docetaxel, prednisone, bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.